JP7897689B2 - エキソソーム細胞外小胞及びその使用方法 - Google Patents

エキソソーム細胞外小胞及びその使用方法

Info

Publication number
JP7897689B2
JP7897689B2 JP2020573481A JP2020573481A JP7897689B2 JP 7897689 B2 JP7897689 B2 JP 7897689B2 JP 2020573481 A JP2020573481 A JP 2020573481A JP 2020573481 A JP2020573481 A JP 2020573481A JP 7897689 B2 JP7897689 B2 JP 7897689B2
Authority
JP
Japan
Prior art keywords
cells
lnp
mrna
hepo
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528096A5 (cg-RX-API-DMAC7.html
JP2021528096A (ja
Inventor
ハディ・ヴァラディ
レンナルト・リンドフォーシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadi Valadi
AstraZeneca AB
Original Assignee
Hadi Valadi
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadi Valadi, AstraZeneca AB filed Critical Hadi Valadi
Publication of JP2021528096A publication Critical patent/JP2021528096A/ja
Publication of JP2021528096A5 publication Critical patent/JP2021528096A5/ja
Priority to JP2024034020A priority Critical patent/JP2024081661A/ja
Application granted granted Critical
Publication of JP7897689B2 publication Critical patent/JP7897689B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020573481A 2018-06-28 2019-06-27 エキソソーム細胞外小胞及びその使用方法 Active JP7897689B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024034020A JP2024081661A (ja) 2018-06-28 2024-03-06 エキソソーム細胞外小胞及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691348P 2018-06-28 2018-06-28
US62/691,348 2018-06-28
PCT/EP2019/067232 WO2020002540A1 (en) 2018-06-28 2019-06-27 Exosome extracellular vesicles and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034020A Division JP2024081661A (ja) 2018-06-28 2024-03-06 エキソソーム細胞外小胞及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021528096A JP2021528096A (ja) 2021-10-21
JP2021528096A5 JP2021528096A5 (cg-RX-API-DMAC7.html) 2022-07-04
JP7897689B2 true JP7897689B2 (ja) 2026-07-30

Family

ID=67139730

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573481A Active JP7897689B2 (ja) 2018-06-28 2019-06-27 エキソソーム細胞外小胞及びその使用方法
JP2024034020A Withdrawn JP2024081661A (ja) 2018-06-28 2024-03-06 エキソソーム細胞外小胞及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024034020A Withdrawn JP2024081661A (ja) 2018-06-28 2024-03-06 エキソソーム細胞外小胞及びその使用方法

Country Status (5)

Country Link
US (1) US12109310B2 (cg-RX-API-DMAC7.html)
EP (1) EP3813798A1 (cg-RX-API-DMAC7.html)
JP (2) JP7897689B2 (cg-RX-API-DMAC7.html)
CN (1) CN112543629A (cg-RX-API-DMAC7.html)
WO (1) WO2020002540A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
TW202220637A (zh) * 2020-08-06 2022-06-01 美商現代公司 製備脂質奈米顆粒之方法
JP7633787B2 (ja) * 2020-09-23 2025-02-20 三洋化成工業株式会社 細胞外小胞の製造方法
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
EP4387657A4 (en) * 2021-08-17 2025-05-21 Monash University Lipid nanoparticle formulations
WO2023178500A1 (en) * 2022-03-22 2023-09-28 Beijing Theraxyte Bioscience Co. Ltd. Therapeutic vesicles and methods of processing the same
CN114848608B (zh) * 2022-05-17 2024-01-30 东南大学 一种蛋白或多肽递送载体及其制备方法与应用
CN115887758B (zh) * 2022-11-15 2024-01-26 西南交通大学 负载外泌体促进糖尿病创面修复的共聚水凝胶
CN117679354B (zh) * 2024-02-04 2024-05-28 知想(山东)医疗科技有限公司 金花茶外泌体制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010285426A (ja) 2009-05-11 2010-12-24 National Cancer Center 核酸導入方法
JP2012524052A (ja) 2009-04-17 2012-10-11 アイシス イノヴェイション リミテッド 遺伝物質の送達用の組成物
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
JP2017502997A (ja) 2014-01-21 2017-01-26 アンヤリウム バイオサイエンシーズ アーゲー ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3247328B1 (en) * 2015-01-21 2026-01-07 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
EP3500244B1 (en) * 2016-08-22 2026-07-08 Lonza Sales AG Methods of suppressing delivery of exosomes to liver and spleen
EP3292861A1 (en) 2016-09-13 2018-03-14 Centre National De La Recherche Scientifique (Cnrs) An in vitro method for obtaining a biohybrid vector

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524052A (ja) 2009-04-17 2012-10-11 アイシス イノヴェイション リミテッド 遺伝物質の送達用の組成物
JP2010285426A (ja) 2009-05-11 2010-12-24 National Cancer Center 核酸導入方法
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
JP2017502997A (ja) 2014-01-21 2017-01-26 アンヤリウム バイオサイエンシーズ アーゲー ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NATURE COMMUNICATIONS, 2017年, 8: 1145, DOI:10.1038/s41467-017-01196-x, p. 1-15
THE NEW ENGLAND JOURNAL OF MEDICINE, 1996年, Vol.334 No.17, pp.1135-1138
膜(MEMBRANE),2015年, 40(5),p.235-241

Also Published As

Publication number Publication date
US20210315819A1 (en) 2021-10-14
CN112543629A (zh) 2021-03-23
JP2024081661A (ja) 2024-06-18
WO2020002540A1 (en) 2020-01-02
EP3813798A1 (en) 2021-05-05
US12109310B2 (en) 2024-10-08
JP2021528096A (ja) 2021-10-21

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240423

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240614

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260717

R150 Certificate of patent or registration of utility model

Ref document number: 7897689

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150